Diagnosis
Economics
Harm/
aetiology
Prognosis
Therapy
ACE
inhibitors
Antithrombotic
therapy
Arrhythmia
therapy
Balloon
pumps
Beta-blockers
Calcium-channel
blockers
Insulin
Smoking
cessation
Thrombolysis
PTCA
|
|
Myocardial infarction
- intravenous heparin had an unclear role.
-
| Level of evidence 1a- |
Expiry Date March 2003 |
-
Myocardial infarction
- one year mortality was decreased slightly with thrombolysis.
-
| Level of evidence 2b |
Expiry Date March 2003 |
-
Myocardial infarction
- tPA and heparin prevented more deaths than streptokinase and heparin, but caused more strokes.
-
| Level of evidence 1b |
Expiry Date March 2003 |
-
Myocardial infarction
- tPA, age over 60, anterior MI, Killip class and diastolic blood pressure affected stroke rates.
-
| Level of evidence 2b |
Expiry Date March 2003 |
-
Myocardial infarction
- tPA was better than streptokinase at reducing mortality.
-
| Level of evidence 1b |
Expiry Date March 2003 |
-
Myocardial infarction
- tPA causes more strokes than streptokinase.
-
| Level of evidence 1b |
Expiry Date March 2003 |
-
Myocardial infarction
- tPA reduced reinfarction and adverse effects, but caused more strokes than streptokinase.
-
| Level of evidence 1b |
Expiry Date March 2003 |
-
Myocardial infarction
- no clear benefit from rescue angioplasty following failed thrombolysis.
-
| Level of evidence 1b- |
Expiry Date March 2003 |
-
Myocardial infarction
- early thrombolysis saves more lives.
-
| Level of evidence 1a |
Expiry Date March 2003 |
-
Myocardial infarction
- thrombolysis: increased tachyarrhythmias in general, but decreased VF.
-
| Level of evidence 1a |
Expiry Date March 2003 |
-
Myocardial infarction
- tenecteplase was not different than alteplase.
-
| Level of evidence 1b- |
Expiry Date March 2003 |
-
Myocardial infarction
- fibrinolytic therapy decreases mortality.
-
| Level of evidence 1a |
Expiry Date March 2003 |
-
Myocardial infarction
- reteplase was as effective as alteplase.
-
| Level of evidence 1b |
Expiry Date March 2003 |
-
Myocardial infarction
- Heparin is of equivocal benefit with aspirin and thrombolysis
-
| Level of evidence 1a |
Expiry Date March 2003 |
|